Fetal Lead Exposure at Each Stage of Pregnancy as a Predictor of Infant Mental Development

Citation
Hu, Howard, Martha Maria Tellez-Rojo, David Bellinger, Donald Smith, Adrienne S. Ettinger, Hector Lamadrid-Figueroa, Joel Schwartz, Lourdes Schnaas, Adriana Mercado-Garcia, and Mauricio Hernandez-Avila. 2006. Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development. Environmental Health Perspectives 114(11): 1730-1735.

Published Version
doi:10.1289/ehp.9067

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:8157299

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
The findings of a wide variety of international studies on the impacts of lead exposure on mental development persuaded many countries to progressively reduce the amount of lead exposure deemed safe during childhood. Since 1991, the U.S. Centers for Disease Control and Prevention (CDC) has recommended 10 µg/dL (0.48 µmol/L) as the pediatric blood lead level, to compare the impacts of our pregnancy measures of fetal lead dose. We measured lead in maternal plasma and whole blood during each trimester in 146 pregnant women in Mexico City. We then measured umbilical cord blood lead at delivery and, when offspring were 12 and 24 months of age, measured blood lead and administered the Bayley Scales of Infant Development. We used multivariate regression, adjusting for covariates and 24-month blood lead, to compare the impacts of our pregnancy measures of fetal lead dose.

RESULTS: Maternal lead levels were moderately high with a first-trimester blood lead mean (± SD) value of 7.1 ± 5.1 µg/dL and 14% of values ≥ 10 µg/dL. Both maternal plasma and whole blood lead during the first trimester (but not in the second or third trimester) were significant predictors (p < 0.05) of poorer Mental Development Index (MDI) scores. In models combining all three trimester measures and using standardized coefficients, the effect of first-trimester maternal plasma lead was somewhat greater than the effect of first-trimester maternal whole blood lead and substantially greater than the effects of second- or third-trimester plasma lead, and values averaged over all three trimesters. A 1-SD change in first-trimester plasma lead was associated with a reduction in MDI score of 3.5 points. Postnatal blood lead levels in the offspring were less strongly correlated with MDI scores.

CONCLUSIONS: Fetal lead exposure has an adverse effect on neurodevelopment, with an effect that may be most pronounced during the first trimester and best captured by measuring lead in either maternal plasma or whole blood.

KEY WORDS: bone, IQ, lead, plasma, pregnancy, neurodevelopment. Environ Health Perspect 114:1730–1735 (2006). doi:10.1289/ehp.9067 available via http://dx.doi.org/ [Online 19 July 2006]

BACKGROUND: The impact of prenatal lead exposure on neurodevelopment remains unclear in terms of consistency, the trimester of greatest vulnerability, and the best method for estimating fetal lead exposure.

OBJECTIVE: We studied prenatal lead exposure’s impact on neurodevelopment using repeated measures of fetal dose as reflected by maternal whole blood and plasma lead levels.

METHODS: We measured lead in maternal plasma and whole blood during each trimester in 146 pregnant women in Mexico City. We then measured umbilical cord blood lead at delivery and, when offspring were 12 and 24 months of age, measured blood lead and administered the Bayley Scales of Infant Development. We used multivariate regression, adjusting for covariates and 24-month blood lead, to compare the impacts of our pregnancy measures of fetal lead dose.

RESULTS: Maternal lead levels were moderately high with a first-trimester blood lead mean (± SD) value of 7.1 ± 5.1 µg/dL and 14% of values ≥ 10 µg/dL. Both maternal plasma and whole blood lead during the first trimester (but not in the second or third trimester) were significant predictors (p < 0.05) of poorer Mental Development Index (MDI) scores. In models combining all three trimester measures and using standardized coefficients, the effect of first-trimester maternal plasma lead was somewhat greater than the effect of first-trimester maternal whole blood lead and substantially greater than the effects of second- or third-trimester plasma lead, and values averaged over all three trimesters. A 1-SD change in first-trimester plasma lead was associated with a reduction in MDI score of 3.5 points. Postnatal blood lead levels in the offspring were less strongly correlated with MDI scores.

CONCLUSIONS: Fetal lead exposure has an adverse effect on neurodevelopment, with an effect that may be most pronounced during the first trimester and best captured by measuring lead in either maternal plasma or whole blood.
available to cross the placenta (Goyer 1990); instead, it is the < 1% of lead in the plasma compartment of blood that is of greatest interest in terms of fetal exposure. Recent data suggest that there are significant interindividual differences in the ratio of red cell lead to plasma lead (Hu 1998; Lamadrid-Figueroa 2006), making maternal whole blood lead levels potentially unreliable as a proxy for plasma lead and fetal exposure (Chuang et al. 2001; Goyer 1990).

To date, no study of fetal lead neurotoxicity has included the biomarker measurements needed to compare whole blood and plasma lead levels during each trimester of pregnancy as predictors of infant neurodevelopment. It is such a comparison that we report here.

Materials and Methods

Study subjects. Subjects were recruited between May 1997 and July 1999 from 2,273 women approached during prenatal visits at one of three clinics of the Mexican Institute of Social Security (IMSS) in Mexico City. Women were eligible if they had a confirmed positive β-human chorionic gonadotropin test or were trying to become pregnant, lived in Mexico City, and were willing to participate in the 3-year follow-up study protocol. Of the 2,273 women approached, 1,502 (66%) declined to be enrolled. We applied the following exclusion criteria to the 771 (34%) women who were willing to participate (percent excluded in parentheses): having plans to leave the area in the following 5 years (3.7%); having a psychiatric disorder (0%); daily consumption of alcoholic beverages (0%); addiction to illegal drugs (0%); consumption of cigarettes (0%); diagnosis of high-risk pregnancy (0%); or continuous use of prescription drugs at the time of pregnancy (0%). Of the latter group, 47 became pregnant, agreed to participate, and were enrolled in the cohort comprising a total of 327 pregnant women.

All mothers were informed about the study; those who agreed to participate read and signed a letter of informed consent. The research protocol was approved by the Ethics Committees of the National Institute of Public Health of Mexico, the Harvard School of Public Health, the Brigham and Women’s Hospital, the University of California, and the participating hospitals.

Blood and plasma lead measurement in mothers. Blood and plasma samples were collected during each prenatal visit of the mothers to the Center for Environmental Health Research of the American British Cowdray (ABC) Hospital in Mexico City. Visits were scheduled at 12, 24, and 34 weeks of pregnancy, and samples were classified as corresponding to first, second, or third trimester according to the timing of these visits. Subjects were instructed to fast overnight before sample collection. Before venipuncture, each subject’s arm was washed with ultrapure water and disinfected with reagent-grade alcohol. Three milliliters of venous whole blood was collected with a butterfly catheter (19 gauge) into a low-lead container (Vacutainer B-D 367734; Becton-Dickinson, Franklin Lakes, NJ, USA) for blood lead analysis, and 13 cm³ venous blood was then collected into a polyethylene tube containing 100 ISP (international units) sodium heparin (H-3393; Sigma Chemical Company, St. Louis, MO, USA), processed, and shipped to the trace metal facility at the University of California, Santa Cruz, for measurement of whole blood lead concentrations using ultra-clean methods detailed elsewhere (Hernandez-Avila et al. 1998; Smith et al. 1998). All samples were analyzed using inductively coupled plasma mass spectrometry (ICP-MS; Thermo Finnigan, Bremen, Germany). Potential contamination by lead from hemozytized red cells was assessed by measuring levels of plasma iron and free hemoglobin using sensitive methods previously described in detail (Smith et al. 1998). Accordingly, 18 samples were determined to be contaminated and excluded from further analyses.

Children’s blood lead measurement. Umbilical cord and infant venous blood samples at 24 months were collected in trace metal–free tubes. Due to the logistical constraints posed by the collection of samples during birth from multiple hospitals and at unpredictable hours, we obtained data on cord blood on only 57% of the mothers participating in this study. Samples were analyzed for lead using an atomic absorption spectrometry (AAS) instrument (model 3000; Perkin Elmer, Chelmsford, MA, USA) at the metals laboratory of the ABC Hospital, which participates in the external validation protocol of the Wisconsin Laboratory of Hygiene. The Pearson correlation coefficient between all available measurements by AAS and those by ICP-MS was 0.93 (in mothers). Precision was similar using either measuring technique; standard deviations were not significantly different (p = 0.32); and accuracy was comparable (with difference in means < 1.0 µg/dL).

Measurement of child development and potential confounders. Infant development at 24 months was assessed by trained personnel using the Bayley Scales of Infant Development II–Spanish version (BSID-II) (Bayley 1993) using a standardized protocol described in a previous study by our research group (Gomaa et al. 2002). All assessors were blind to the children’s in utero and postnatal lead measurements. MDI scores at 24 months of age were considered the primary outcome. Information on demographic, socioeconomic, and other factors that could confound the relationship between lead and child development was collected. Maternal IQ was assessed using the Information, Comprehension, Similarities, and Block Design subtests of the Wechsler Adult Intelligence Scale (Wechsler 1968).

Statistical analysis. Descriptive statistics and appropriate transformations were performed before bivariate analyses. Outliers were identified using the ESD (Extreme Studentized Deviate) Many-Outlier procedure (Rosner 1983). We calculated Spearman correlation coefficients among the lead measurements. Height and weight data were transformed into z-scores by using World Health Organization (WHO)/National Center for Health Statistics/CDC reference data (WHO 1979) and interpreted as indices of a child’s nutritional status. Variables considered to be potential confounders based on biologic plausibility, regardless of statistical significance, and those significantly (p < 0.1) associated with MDI scores in bivariate analyses were included in multiple linear regression models; given these criteria, confounders included were child’s sex, blood lead at 24 months of age, height for age z-score and weight, as well as maternal age and intelligence quotient. All models featured log-transformed lead measures because this procedure provided the best fit. We first generated “single-trimester” models, in which we evaluated the associations between MDI score and log-transformed plasma and whole blood lead levels during each trimester of pregnancy adjusting for potential confounders. We generated “multitrimester” models, incorporating, in each model, the data from either plasma or whole blood lead concentrations from all three trimesters. We also ran models using maternal plasma lead or whole blood lead, averaged over all three trimesters. Infant sex was controlled for throughout all analyses to enable better comparability of the relative effects of plasma lead and blood lead, we compared effect estimates for a 1-SD change in each exposure metric. We carried out a similar analysis using log-transformed cord blood lead levels as a proxy variable for prenatal lead
Pregnancy exposure. To account for environmental exposure to lead in postnatal life, we also modeled MDI as a function of the child's blood lead concentrations at 24 months of age.

Due to postponed visits to the research center visits of some women, misclassification of the timing of some of the visits occurred (e.g., a visit intended for the first trimester occurred during the second trimester; see Figure 1 for graphic display of misclassification). To account for the potential bias in results, we repeated the “intention to treat” analyses presented in this article, including only those observations that were correctly classified as corresponding to the first, second, and third trimesters of pregnancy according to actual gestational age.

Regression diagnostics were performed on all models to evaluate multicollinearity, distributional assumptions on the error term, and potentially influential data points. When the latter were detected, we fit new models excluding these observations. All statistical analyses were performed using STATA (STATA Statistical Software, release 8.0; StataCorp, College Station, TX, USA).

Results

In the 146 mother–infant pairs in our final study group, no differences significantly greater than zero were noted in maternal age, number of years in school, IQ, and children’s hemoglobin, height, weight, and MDI when compared with mother–child pairs who participated but who did not meet the inclusion criteria for this analysis (n = 70; data not shown). Circulating levels of lead in the included mothers were moderately high, with mean (± SD) values for first-trimester whole blood lead of 70.7 ± 51.0 μg/L and 14% of values ≥ 10 μg/L (Table 1). (Whole blood lead values are expressed in this article as micrograms per liter for ease of comparison with plasma levels.) Both maternal plasma and whole blood lead followed a U-shaped pattern over the course of pregnancy, reaching their lowest points during the second trimester and rising during the third trimester.

As expected, measurements of lead biomarkers in the three stages of pregnancy were moderately well correlated (all p < 0.05); Spearman correlations between blood lead measurements at different stages of pregnancy (mean = 0.72; range, 0.67–0.81) were, on average, higher than their plasma lead counterparts (mean = 0.62; range, 0.55–0.69). Cord blood lead was most highly correlated with maternal whole blood lead measured during the third trimester of pregnancy (r = 0.5436, p < 0.001).

Cord blood lead concentrations were 10.6 μg/L lower, on average, than maternal whole blood lead levels at delivery. Children’s whole blood lead levels at 12 and 24 months of age were correlated (r = 0.58, p < 0.01) and lower, on average, than their cord blood lead levels.

Figure 1. Plasma lead levels during pregnancy according to gestational age. Plasma lead measurements were taken at what were intended to be the first, second, and third trimesters. Dotted lines mark the 13th and 26th weeks of gestation.

Table 1. Characteristics of the study population of mother–infant pairs.

| Characteristics | No. | Mean ± SD | Range |
|-----------------|-----|-----------|-------|
| Mothers         |     |           |       |
| Age (years)     | 146 | 27.1 ± 5.3| 15–43 |
| IQ              | 146 | 89.1 ± 12.9| 55–120|
| Whole blood lead (μg/L) |     |           |       |
| First trimester | 119 | 70.7 ± 51.0| 14.9–435.9 |
| Second trimester| 136 | 60.8 ± 31.5| 15.8–224.4 |
| Third trimester | 132 | 68.6 ± 42.3| 15.3–330.8 |
| Delivery        | 111 | 72.6 ± 43.3| 15–324 |
| Plasma lead (μg/L) |     |           |       |
| First trimester | 119 | 0.16 ± 0.14| 0.04–0.99 |
| Second trimester| 136 | 0.14 ± 0.11| 0.03–0.67 |
| Third trimester | 132 | 0.16 ± 0.24| 0.03–2.63 |
| Children        |     |           |       |
| Birth weight (g) | 146 | 3,144 ± 359| 2,125–4,000 |
| Male sex (%)    | 76  | 52.05     |       |
| Blood lead (μg/L) |     |           |       |
| Cord            | 83  | 62.0 ± 38.8| 9–200 |
| 12 months       | 125 | 52.2 ± 34.1| 9–204 |
| 24 months       | 146 | 47.9 ± 37.1| 6–368 |
| Height at 24 months (cm) | 146 | 86.1 ± 3.0 | 74–93 |
| Weight at 24 months (kg) | 146 | 11.98 ± 1.55 | 9.4–13.9 |
| Hemoglobin (g/dL) | 135 | 12.4 ± 1.2 | 7.1–14.8 |
| MDI score (at 24 months) | 146 | 91.5 ± 11.6 | 68–122 |

Table 2. Single-trimester multivariate linear regression models for MDI of offspring (at 24 months of age) comparing markers of lead exposure at different times for blood lead and plasma lead.

| Variable               | No. | β   | p-Value | 95% CI        |
|------------------------|-----|-----|---------|---------------|
| **Pregnancy**          |     |     |         |               |
| Blood lead (μg/L)      |     |     |         |               |
| First trimester        | 119 | −4.13| 0.04    | −8.10 to −0.17|
| Second trimester       | 136 | −4.08| 0.06    | −8.29 to 0.12 |
| Third trimester        | 132 | −2.42| 0.23    | −6.38 to 1.54 |
| Averagea               | 146 | −3.52| 0.10    | −7.66 to 0.63 |
| Plasma lead (μg/L)     |     |     |         |               |
| First trimester        | 119 | −3.77| 0.03    | −7.12 to −0.42|
| Second trimester       | 136 | −2.48| 0.13    | −5.74 to 0.77 |
| Third trimester        | 132 | −0.32| 0.83    | −3.38 to 2.74 |
| Averagea               | 146 | −3.11| 0.07    | −6.53 to 0.31 |
| **Delivery**           |     |     |         |               |
| Cord blood lead (μg/L) | 83  | −0.35| 0.88    | −4.72 to 4.03 |
| Postnatal              |     |     |         |               |
| Child blood lead (μg/L)|     |     |         |               |
| 12 months              | 125 | −2.38| 0.23    | −6.24 to 1.49 |
| 24 months              | 146 | −1.00| 0.50    | −3.93 to 1.94 |

CI, confidence interval. Each model is adjusted for infant’s concurrent blood lead (24 months of age), sex, maternal age, current weight, height-for-age Z-score, and maternal IQ. Logarithmically transformed lead concentrations were used. Each line in the table represents a different model.

*aThe arithmetic mean of log-blood lead or log-plasma lead using all available measurements.
Single-trimester models of MDI scores (Table 2) suggested a negative relationship between circulating lead in each trimester of pregnancy and MDI scores at 24 months of age, adjusting for maternal age and IQ and child’s concurrent blood lead, sex, weight and height-for-age Z-score. MDI was most strongly associated with lead concentrations during the first trimester for both plasma (standardized coefficient, −4.13; \( p = 0.03 \)) and whole blood lead (standardized coefficient, −3.77; \( p = 0.04 \)). Both maternal plasma and whole blood lead averaged over all three trimesters had associations with MDI of borderline significance (standardized coefficients of −3.52, \( p = 0.07 \); and −3.11, \( p = 0.10 \), respectively).

When we repeated the analysis using only those measurements correctly classified in each trimester of pregnancy, we found that lead concentrations during the first trimester were significantly associated with a decrease in MDI at 24 months of age. The estimated coefficients in the first trimester (\( n = 56 \)) were −6.39 (\( p = 0.04 \)) and −6.94 (\( p = 0.04 \)) points per log micrograms per liter of plasma and whole blood lead, respectively. The coefficients for the second trimester plasma and whole blood lead levels (\( n = 102 \)) were much smaller (−1.73, \( p = 0.38 \); and −3.66, \( p = 0.16 \), respectively). Umbilical cord lead at birth and infant whole blood lead at 12 and 24 months were inversely but weakly (\( p > 0.20 \)) associated with MDI at 24 months.

In multitrimester models (Table 3), the plasma lead model predicts that an increase of 1 SD in loge-transformed plasma lead in the first trimester is associated with a 15-point decline in MDI score at 24 months of age, in contrast to a 4-point decline per 0.1-µg/L increase in plasma lead for observations above the median plasma lead—confirming that the nonlinear pattern is not an artifact of our transformation of the variable.

**Discussion**

This study is the first of which we are aware that attempted to compare the relative influence on neurodevelopmental toxicity of two different biomarkers of fetal lead exposure at each stage of pregnancy. We found that both maternal blood lead and maternal plasma lead vary considerably over pregnancy; first-trimester levels of either measures were better than second- or third-trimester levels or levels averaged over all three trimesters in predicting infant neurobehavioral performance at age 24 months; and first-trimester maternal plasma lead levels were somewhat better than first-trimester maternal whole blood lead levels at predicting infant neurobehavioral performance at 24 months of age.

Our study had several limitations. Our sample size was modest, a reflection of the labor- and cost-intensive nature of collecting plasma samples using a rigorous protocol. Nevertheless, we were able to successfully distinguish and compare the relative contributions to neurodevelopment of trimester- and biomarker-specific measures of exposure. Our subjects were a small subset of women who had been initially approached in the clinics (\( n = 2,273 \)), raising the issue of the generalizability of our study. However, the women included in our final sample did not differ significantly from other eligible subjects on key covariates, suggesting that our sample was quite adequate.

### Table 3. Multivariate models of MDI of offspring (at 24 months of age) using either whole blood or plasma lead concentrations as markers of prenatal lead exposure at different trimesters of pregnancy.

| Variable                  | Plasma model ($R^2 = 0.22$) | Blood model ($R^2 = 0.21$) |
|---------------------------|-----------------------------|-----------------------------|
|                           | \( \beta \) | \( p \)-Value | \( \beta \) | \( p \)-Value |
| Pb first trimester*       | −3.54 | 0.03 | −2.40 | 0.19 |
| Pb second trimester*      | 0.80  | 0.65 | −1.29 | 0.56 |
| Pb third trimester*       | 1.18  | 0.44 | 1.42  | 0.46 |
| Current blood leadb       | −0.01 | 0.62 | −0.01 | 0.80 |
| Sexc                      | 3.64  | 0.13 | 3.90  | 0.15 |
| Height-for-age Z-score    | 2.87  | 0.06 | 2.71  | 0.06 |
| Current weight (kg)       | −1.70 | 0.06 | −2.00 | 0.02 |
| Mother’s IQ               | 0.08  | 0.40 | 0.08  | 0.39 |
| Mother’s age (years)      | 0.59  | 0.01 | 0.62  | 0.01 |
| Intercept                 | 84.25 | <0.01 | 87.18 | <0.01 |

These are the results of two multivariate regression models with either plasma lead or whole blood concentrations in different trimesters of pregnancy simultaneously included in each of the two models. Coefficients are mean change in MDI per increase of 1 SD in loge lead concentrations, which allows for direct comparisons between the beta-coefficients of plasma lead versus blood lead.

*Plasma lead concentration (µg/L) in corresponding trimester. *Infant whole blood lead (µg/L) at 24 months of age. *Infant sex: 1 = male, 2 = female.

![Figure 2. Plasma lead levels in the first trimester of pregnancy versus MDI scores at 24 months of age. CI, confidence interval. Curve indicates the best-fit model for the association between plasma lead levels and MDI scores, adjusting for plasma lead levels in the second and third trimesters, mother’s age and IQ, child’s blood lead levels at 24 months of age, sex and height-for-age Z-score. Vertical line marks average plasma lead concentration when whole blood lead equals 100 µg/L.](image-url)
representative of the women serviced by our participating clinics. Some of our observations were classified with respect to trimester; however, our results were very similar in the reanalysis using classification corrections. Indeed, the association between first-trimester lead exposure and infant neurodevelopment appeared to be even greater, a finding that suggests that there was downward bias due to improper assignment of second-trimester women to the first trimester category. We did not control for a summary measure of home conditions, such as the Home Observation for Measurement of the Environment (HOME) score; however, the absence of this covariate is unlikely to explain differences in effects among the three trimesters of lead exposure.

Finally, offspring blood lead levels at 24 months did not significantly predict lower MDI score; on the other hand, our sample size, again, was modest, and in a separate analysis of the larger group of mother–infant pairs participating in this research ($n = 294$) that was not confined to women who had measured lead levels, we found an important significance of adverse effect on offspring blood lead levels at 24 months of age on 24-month MDI score (Tellez-Rojo et al. 2006).

The best-fitting model relating first-trimester plasma lead to 24-month MDI scores was one in which lead level was expressed as the natural logarithm of the measured value. This suggests that the shape of the dose–effect relationship is supralinear, with a steeper slope at lower plasma lead levels. This is consistent with the blood lead–IQ relationships in children reported by Canfield et al. (2003), in reanalyses of the Boston prospective study of children (Bellinger and Needleman 2003), and in pooled analyses that included several additional prospective studies (Lanphear et al. 2005). In quantitative terms, however, the rates of change over both ranges of plasma lead level were approximately twice as great as those reported by Canfield et al. (2003). Meta-analyses of multiple studies have converged on an estimate of a 2–3 IQ point decrement for each 10-$\mu$g/dL increase in postnatal blood lead level (International Program on Chemical Safety 1995; Pocock et al. 1994; Schwartz 1994), but these estimates might reflect mostly the region of the dose–effect relationship in which the slope is shallower. Moreover, blood lead is a surrogate measured with error for toxicologically available lead, and the larger effect size estimates for plasma lead suggest that many previous studies may have had effect estimates downwardly biased by measurement error.

We are not aware of previous studies for comparison that have included maternal measures of circulating lead at each stage of pregnancy. Although Schnaas et al. (2006) also studied lead exposure and neurobehavior in a cohort of Mexico City children from the in utero period to childhood (and found a significant adverse impact of in utero lead exposure), their observations began after the 12th week of pregnancy and thus precluded examination of the direct effects of first-trimester lead exposure.

In experimental studies, lead is known to affect a wide range of processes critical to central nervous system development, including differentiation (Alfano and Petir 1982; Petir and LeBoullier 1979; Petir et al. 1983), myelination (Mendola et al. 2002), and synaptogenesis (Johnston and Goldstein 1998). Of these, differentiation is primarily a first-trimester event, making a targeting of this process as a possible explanation for our finding of a first-trimester dominant effect.

Mobilization of maternal bone lead stores has been clearly identified as a major source of fetal lead exposure (Gulson et al. 2003; Hu and Hernandez-Avila 2002), and elevated maternal bone lead stores can be expected in women with ongoing environmental or occupational exposures and in women who have retained bone lead burdens from earlier lead exposures. The women in our study fell into the latter category, having lived in Mexico City, where leaded gasoline was combusted until 1997. Some have suggested that fetal lead exposure resulting from the mobilization of maternal bone lead stores during pregnancy can be reduced by calcium supplementation (Gulson et al. 2004; Janakiraman et al. 2003). Our study suggests that if such a strategy were to prove useful in reducing lead exposure to the fetus, it would have to be implemented very early in pregnancy to maximize the benefit to fetal neurodevelopment.

Our findings do not mean that measurement of maternal plasma lead is likely to become a clinically useful environmental health tool. The methods required to measure plasma lead are laborious and require special and expensive equipment. However, this biomarker is a useful research tool in efforts to understand and detect the health impacts of environmental lead exposure.

In conclusion, we found that first-trimester measures of fetal lead exposure—particularly levels of lead in maternal plasma, but also levels of lead in maternal whole blood—were predictive of adverse neurodevelopment later in life, with an effect that was independent from that of postnatal lead exposure and that was stronger than the effects associated with second- or third-trimester measures. This is of major potential public health concern because lead remains a widespread environmental health hazard and current efforts at primary prevention have focused almost entirely on childhood rather than fetal exposure. If future research confirms this finding, ascertaining women at risk and identifying effective strategies for prevention of fetal lead exposure may become an important public health priority; moreover, it may be necessary to consider prepregnancy interventions, because our research suggests that screening and intervention any later than the first trimester may be too late to prevent the greatest fetal neurotoxic effects.

**References**

Alfano DP, Petir TL. 1982. Neonatal lead exposure alters the dendritic development of hippocampal dentate granule cells. Exp Neurol 75(2):275–288.

Baghurst PA, McMichael AJ, Vimpani GV, Robertson EF, Clark PD, Wiggy NR. 1987. Determinants of blood lead concentrations of pregnant women living in Port Pirie and surrounding areas. Med J Aust 146(2):69–73.

Bayley N. 1993. Bayley Scales of Infant Development. 2nd ed. San Antonio, TX:Psychological Corporation.

Bellinger D, Leviton A, Waternaux C, Needleman H, Robinovitch M. 1987. Longitudinal analyses of prenatal and postnatal lead exposure and early cognitive development. N Engl J Med 316(17):1037–1043.

Bellinger DC, Needleman HL. 2003. Intellectual impairment and blood lead levels. N Engl J Med 349(5):500–502.

Bellinger DC, Stiles NM, Needleman HL. 1992. Low-level lead exposure, intelligence and academic achievement: a long-term follow-up study. Pediatrics 90(6):859–861.

Canfield RL, Henderson CR, Jr., Cory-Slechta DA, Cox C, Juika TA, Langhein BP. 2003. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 348(16):1517–1526.

CDC. 1991. Preventing Lead Poisoning in Young Children: A Statement by the Centers for Disease Control. Atlanta, GA:Centers for Disease Control.

Chuang HY, Schwartz J, Gonzales-Cossio T, Lugo MC, Palazuelos E, Aro A, et al. 2001. Interrelations of levels in bone, venous blood, and umbilical cord blood with exogenous lead exposure through maternal plasma lead in peripartum women. Environ Health Perspect 109:527–532.

Cooney GH, Bell A, McBride W, Carter C. 1989. Neurobehavioural consequences of prenatal low level lead exposures to lead. Neurotoxicol Teratol 11(2):95–104.

Dietrich KN, Kraft RM, Bornschein RL, Hammond PB, Berger O, Succop PA, et al. 1987. Low-level fetal lead exposure effect on neurobehavioural development in early infancy. Pediatrics 80(2):721–730.

Dietrich KN, Succop PA, Berger GS, Hammond PB, Bornschein RL. 1991. Lead exposure and the cognitive development of urban preschool children: the Cincinnati Lead Study cohort at age 4. Neurotoxicol Teratol 13(2):202–211.

Emrath CB, Morrow-Thucka M, Marler MR, Wolf AW. 1987. Low level lead exposure in the prenatal and early preschool periods: early preschool development. Neurotoxicol Teratol 9(3):259–270.

Emrath CB, Wolf AW, Kentard MJ, Erhard P, Filipowich HF, Sokol RJ. 1986. Intrauterine exposure to low levels of lead: the status of the neonate. Arch Environ Health 41(5):287–291.

Gomas A, Hu H, Bellinger D, Schwartz J, Tsaih SW, Gonzalez-Cossio T, et al. 2002. Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study. Pediatrics 110(1):110–118.

Goyer RA. 1990. Transplacental transport of lead. Environ Health Perspect 89:101–105.

Guilarte TL, Mizon KJ, Korsch MJ, Palmer JM, Donnelly JB. 2003. Mobilization of lead from human bone tissue during pregnancy and lactation—a summary of long-term research. Sci Total Environ 301(2–3):279–314.

Gulson BL, Mizon KJ, Palmer JM, Korsch MJ, Taylor AJ, Mahaffey KR. 2004. Blood lead changes during pregnancy and postpartum with calcium supplementation. Environ Health Perspect 112:1499–1507.

Hernandez-Avila M, Smith D, Meneses F, Sanin LH, Hu H. 1998. The influence of bone and blood lead on plasma lead levels in environmentally exposed adults. Environ Health Perspect 106:473–477.

Hu H. 1998. Bone lead as a new biologic marker of lead dose: recent findings and implications for public health. Environ Health Perspect 106(suppl 4):961–967.

Hu H, Hernandez-Avila M. 2002. Invited commentary: lead, bones, women, and pregnancy— the poison within? Am J Epidemiol 156(12):1088–1091.
International Program on Chemical Safety. 1995. Environmental Health Criteria 165: Inorganic Lead. Geneva: International Program on Chemical Safety, World Health Organization. Available: http://www.inchem.org/documents/ehc/ehc/ehc165.htm [accessed 2 February 2006].

Janakiraman V, Ettinger A, Mercado-Garcia A, Hu H, Hernandez-Avila M. 2003. Calcium supplements and bone resorption in pregnancy: a randomized crossover trial. Am J Prev Med 24(3):260–264.

Johnston MV, Goldstein GW. 1998. Selective vulnerability of the developing brain to lead. Curr Opin Neurol 11(6):689–693.

Lamadrid-Figueroa H, Tellez-Rojo M, Hernandez-Cadena L, Mercado A, Smith D, Hernandez-Avila M, et al. 2006. The relationship between lead in plasma and whole blood during pregnancy. J Tox Environ Health 69:1781–1796.

Lampe A, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, et al. 2005. Low-level environmental lead exposure and children’s intellectual development: a systematic review of the epidemiological evidence. BMJ 330(7493):1189–1197.

Rosner B. 1983. Percentage points for a generalized ESD many-outlier procedure. Technometrics 25:165–172.

Schnaas L, Rothenberg SJ, Flores MF, Martinez S, Hernandez C, Osorio E, et al. 2006. Reduced intellectual development in children with prenatal lead exposure. Environ Health Perspect 114:791–797.

Schwartz J. 1994. Low-level lead exposure and children’s IQ: a meta-analysis and search for a threshold. Environ Res 66(1):43–55.

Shen XM, Yan CH, Guo D, Wu SM, Li RD, Huang H, et al. 1998. Low-level prenatal lead exposure and neurobehavioral development of children in the first year of life: a prospective study in Shanghai. Environ Res 79(1):1–8.

Smith DR, Illustre RP, Osterloh JD. 1998. Methodological considerations for the accurate determination of lead in human plasma and serum. Am J Ind Med 33(5):430–438.

Tellez-Rojo M, Bellinger D, Lamadrid-Figueroa H, Schaa-Arieta L, Arroyo-Quizzi C, Mercado-Garcia A, et al. 2006. Longitudinal associations between blood lead concentration < 10 μg/dL and neurobehavioral development in environmentally-exposed children in Mexico City. Pediatrics 118(5):e323–e330. Wasserman GA, Liu X, Lolocono NJ, Factor-Litvak P, Kline JK, Popovac D, et al. 1997. Lead exposure and intelligence in 7-year-old children: the Yugoslavia Prospective Study. Environ Health Perspect 105:996–996.

Wasserman GA, Liu X, Popovac D, Factor-Litvak P, Kline J, Watermaux C, et al. 2000. The Yugoslavia Prospective Lead Study: contributions of prenatal and postnatal lead exposure to early intelligence. Neurotoxicol Teratol 22(6):811–816.

Wechsler H. 1968. Wechsler Adult Intelligence Scale (WAIS), Spanish Version. San Antonio, TX: Psychological Corporation.

WHO. 1979. Measurement of Nutritional Impact. Geneva: World Health Organization.